Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma:: a tool for comparing the efficacy of different treatment strategies and predicting outcome

被引:113
作者
San Miguel, JF
Almeida, J
Mateo, G
Bladé, J
López-Berges, C
Caballero, D
Hernández, J
Moro, MJ
Fernández-Calvo, J
Díaz-Mediavilla, J
Palomera, L
Orfao, A
机构
[1] Univ Salamanca, Hosp Clin, Serv Hematol, Salamanca 37007, Spain
[2] Ctr Invest Canc, Salamanca, Spain
[3] Univ Salamanca, Serv Citometria, E-37008 Salamanca, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Gen Hosp, Segovia, Spain
[6] Hosp Virgen Blanca, Leon, Spain
[7] Univ Valladolid, Hosp Clin, Valladolid, Spain
[8] Hosp Clin Madrid, Madrid, Spain
[9] Hosp Clin, Zaragoza, Spain
关键词
D O I
10.1182/blood.V99.5.1853
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiparametric immunophenotyping can be a sensitive method for analyzing the plasma cell (PC) compartment in patients with multiple myeloma because it discriminates between myelomatous and normal PCs. Using this approach, we compared the efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) with that of conventional chemo-therapy, We found that ASCT provided a significantly greater reduction in the level of residual tumor PCs and with better recovery of normal PCs. This profile of coexistence of normal PCs and myelomatous PCs resembled that observed in monoclonal gammopathy of undetermined significance. We also found that treatment-induced changes in the PC compartment correlated with disease outcome. Thus, patients in whom at least 30% of gated PCs had a normal phenotype after treatment had a significantly longer progression-free survival (60 +/- 6 months versus 34 +/- 12 months; P = .02).
引用
收藏
页码:1853 / 1856
页数:4
相关论文
共 14 条
[11]   B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy [J].
Pope, B ;
Brown, RD ;
Gibson, J ;
Yuen, E ;
Joshua, D .
BLOOD, 2000, 96 (04) :1274-1279
[12]   Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage [J].
Rawstron, AC ;
Owen, RG ;
Davies, FE ;
Johnson, RJ ;
Jones, RA ;
Richards, SJ ;
Evans, PA ;
Child, JA ;
Smith, GM ;
Jack, AS ;
Morgan, GJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (01) :46-55
[13]   Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations [J].
Yaccoby, S ;
Barlogie, B ;
Epstein, J .
BLOOD, 1998, 92 (08) :2908-2913
[14]  
YACCOBY S, 1997, BLOOD, V92, pA588